Paper20021437
Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.
Richardson A and 1 other. Curr Mol Pharmacol, 2008. Cited by 35 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Papers, record 20021437. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20021437
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Apoptosis | Major topic |
| Neoplasms | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Drug Synergism | |
| Humans |
Source PubMed
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31,067,776 | Effects of Intestinal Microbial⁻Elaborated Butyrate on Oncogenic Signaling Pathways. | Nutrients | 2019 | https://conductscience.org/library/papers/31067776 | PubMed |
| 26,892,272 | Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells. | Naunyn Schmiedebergs Arch Pharmacol | 2016 | https://conductscience.org/library/papers/26892272 | PubMed |
| 26,628,295 | Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. | Tumour Biol | 2016 | https://conductscience.org/library/papers/26628295 | PubMed |
| 25,837,691 | Investigating breast cancer cell behavior using tissue engineering scaffolds. | PLoS One | 2015 | https://conductscience.org/library/papers/25837691 | PubMed |
| 24,972,848 | Selective apoptotic cell death effects of oral cancer cells treated with destruxin B. | BMC Complement Altern Med | 2014 | https://conductscience.org/library/papers/24972848 | PubMed |
| 24,631,358 | Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines. | Bioorg Med Chem | 2014 | https://conductscience.org/library/papers/24631358 | PubMed |
| 24,030,153 | Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737. | Cell Death Dis | 2013 | https://conductscience.org/library/papers/24030153 | PubMed |
| 23,900,856 | Structure-based approach to the design of BakBH3 mimetic peptides with increased helical propensity. | J Mol Model | 2013 | https://conductscience.org/library/papers/23900856 | PubMed |
| 23,879,961 | Personalized medicine in CLL: current status and future perspectives. | Cancer Lett | 2014 | https://conductscience.org/library/papers/23879961 | PubMed |
| 23,801,058 | Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. | Oncotarget | 2013 | https://conductscience.org/library/papers/23801058 | PubMed |
| 23,311,997 | CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line. | World J Surg Oncol | 2013 | https://conductscience.org/library/papers/23311997 | PubMed |
| 23,259,599 | ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. | J Exp Clin Cancer Res | 2012 | https://conductscience.org/library/papers/23259599 | PubMed |
| 22,898,329 | Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. | J Mol Signal | 2012 | https://conductscience.org/library/papers/22898329 | PubMed |
| 22,876,162 | Saponins isolated from Asparagus induce apoptosis in human hepatoma cell line HepG2 through a mitochondrial-mediated pathway. | Curr Oncol | 2012 | https://conductscience.org/library/papers/22876162 | PubMed |
| 22,509,253 | Cacospongionolide and scalaradial, two marine sesterterpenoids as potent apoptosis-inducing factors in human carcinoma cell lines. | PLoS One | 2012 | https://conductscience.org/library/papers/22509253 | PubMed |
| 22,366,758 | N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death. | Nat Neurosci | 2012 | https://conductscience.org/library/papers/22366758 | PubMed |
| 22,238,053 | Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. | Tumour Biol | 2012 | https://conductscience.org/library/papers/22238053 | PubMed |
| 21,970,601 | Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells. | World J Surg Oncol | 2011 | https://conductscience.org/library/papers/21970601 | PubMed |
| 21,760,983 | Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy. | Cancers (Basel) | 2011 | https://conductscience.org/library/papers/21760983 | PubMed |
| 21,348,831 | Delivery of intracellular-acting biologics in pro-apoptotic therapies. | Curr Pharm Des | 2011 | https://conductscience.org/library/papers/21348831 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20021437
GET https://conductscience.org/api/papers/v1/20021437/authors